<unk>  (trade name Duzallo) is a fixed-dose combination drug for the treatment of gout. It contains 200 mg of<unk>  and 300 mg of<unk> . In August 2017, the US Food and Drug Administration approved it for the treatment of hyperuricemia associated with gout in patients for whom target serum uric acid levels have not been achieved with<unk>  alone. It was approved for medical use in the European Union in August 2018. In February 2019, it was discontinued by its manufacturer for business reasons and is no longer available.
Lesinurad/allopurinol
Alendronic acid/colecalciferol
Amlodipine/celecoxib
Ibuprofen/paracetamol
Allopurinol
Diclofenac/misoprostol
Celecoxib/tramadol
Watchful waiting